scholarly journals Stigma associated with medication treatment for young adults with opioid use disorder: a case series

Author(s):  
Scott E. Hadland ◽  
Tae Woo Park ◽  
Sarah M. Bagley
2020 ◽  
Author(s):  
Carrie M. Mintz ◽  
Ned J. Presnall ◽  
John M. Sahrmann ◽  
Jacob T. Borodovsky ◽  
Paul E.A. Glaser ◽  
...  

AbstractBackground and AimsAdolescents with opioid use disorder (OUD) are an understudied and vulnerable population. We examined the association between age and six-month treatment retention, and whether any such association was moderated by medication treatment.MethodsIn this retrospective cohort study, we used an insurance database with OUD treatment claims from 2006-2016. We examined 261,356 OUD treatment episodes in three age groups: adolescents (ages 12-17), young adults (18-25) and older adults (26-64). We used logistic regression to estimate prevalence of six-month retention before and after stratification by treatment type (buprenorphine, naltrexone, or psychosocial services only). Insurance differences (commercial vs Medicaid) in medication treatment prevalence were also assessed.ResultsAdolescents were far less likely to be retained compared to adults (17.6%; 95% CI 16.5-18.7% for adolescents; 25.1%; 95% CI 24.7-25.4% for young adults; 33.3%; 95% CI 33.0-33.5% for older adults). This disparity was markedly reduced after adjusting for treatment type. For all ages, buprenorphine was more strongly associated with retention than naltrexone or psychosocial services. Adolescents who received buprenorphine were more than four times as likely to be retained in treatment (44.5%, 95% CI 40.6-49.0) compared to those who received psychosocial services (9.7%, 95% CI 8.8-10.8). Persons with commercial insurance were more likely to receive medication than those with Medicaid (73.3% vs 36.4%, χ2 =57,870.6, (p<.001).ConclusionsAge disparities in six-month treatment retention are strongly related to age disparities in medication treatment. Results point to need for improved implementation of medication treatment for persons with OUD, regardless of age or insurance status.


2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Allison M. Gustavson ◽  
Marie E. Kenny ◽  
Jennifer P. Wisdom ◽  
Hope A. Salameh ◽  
Princess E. Ackland ◽  
...  

Abstract Background The Veterans Health Administration (VHA) is invested in expanding access to medication treatment for opioid use disorder (MOUD) to save lives. Access varies across VHA facilities and, thus, requires implementation strategies to promote system-wide adoption of MOUD. We conducted a 12-month study employing external facilitation that targeted MOUD treatment among low-adopting VHA facilities. In this study, we sought to evaluate the patterns of perceived barriers over 1 year of external implementation facilitation using the integrated Promoting Action on Research Implementation in Health Services (i-PARIHS) framework. Methods We randomly selected eight VHA facilities from the bottom quartile of the proportion of Veterans with an OUD diagnosis receiving MOUD (< 21%). The 1-year external implementation intervention included developmental evaluation to tailor the facilitation, an on-site visit, and monthly facilitation calls. Facilitators recorded detailed notes for each call on a structured template. Qualitative data was analyzed by coding and mapping barriers to the constructs in the i-PARIHS framework (Innovation, Recipients, Context). We identified emerging themes within each construct by month. Results Barriers related to the Innovation, such as provider perception of the need for MOUD in their setting, were minimal throughout the 12-month study. Barriers related to Recipients were predominant and fluctuated over time. Recipient barriers were common during the initial months when providers did not have the training and waivers necessary to prescribe MOUD. Once additional providers (Recipients) were trained and waivered to prescribe MOUD, Recipient barriers dropped and then resurfaced as the facilities worked to expand MOUD prescribing to other clinics. Context barriers, such as restrictions on which clinics could prescribe MOUD and fragmented communication across clinics regarding the management of patients receiving MOUD, emerged more prominently in the middle of the study. Conclusions VHA facilities participating in 12-month external facilitation interventions experienced fluctuations in barriers to MOUD prescribing with contextual barriers emerging after a facilitated reduction in recipient- level barriers. Adoption of MOUD prescribing in low-adopting VHA facilities requires continual reassessment, monitoring, and readjustment of implementation strategies over time to meet challenges. Although i-PARIHS was useful in categorizing most barriers, the lack of conceptual clarity was a concern for some constructs.


2019 ◽  
Vol 128 ◽  
pp. 105785 ◽  
Author(s):  
Richard A. Rawson ◽  
Traci Rieckmann ◽  
Sarah Cousins ◽  
Michael McCann ◽  
Regina Pearce

2019 ◽  
Vol 41 (2) ◽  
pp. 174-180 ◽  
Author(s):  
Randi Sokol ◽  
Mark Albanese ◽  
Chiara Albanese ◽  
Gerard Coste ◽  
Ellie Grossman ◽  
...  

2018 ◽  
Vol 172 (11) ◽  
pp. 1029 ◽  
Author(s):  
Scott E. Hadland ◽  
Sarah M. Bagley ◽  
Jonathan Rodean ◽  
Michael Silverstein ◽  
Sharon Levy ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document